Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a large increase in short interest during the month of December. As of December 30th, there was short interest totalling 73,600 shares, an increase of 429.5% from the December 15th total of 13,900 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is presently 0.6 days.

Bioasis Technologies Price Performance

Shares of BIOAF stock opened at $0.04 on Wednesday. The company has a 50 day moving average of $0.08 and a 200-day moving average of $0.11. Bioasis Technologies has a 12-month low of $0.02 and a 12-month high of $0.25. The firm has a market cap of $2.90 million, a P/E ratio of -0.91 and a beta of 0.40.

Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last issued its quarterly earnings results on Friday, October 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.09 million for the quarter. As a group, equities analysts expect that Bioasis Technologies will post -0.03 EPS for the current year.

About Bioasis Technologies

Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.

Featured Articles

• Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
• Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
• Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
• Can Alaska Air Continue Soaring Above The Airline Industry?
• Insulet Has Potential To Gain More Than Analysts Are Forecasting
• Cathie Wood Is Buying These Stocks, Should You?

Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.